跳至主要内容
临床试验/ISRCTN90437126
ISRCTN90437126进行中(未招募)3 期

Investigation of efficacy and safety for Preventing COVID-19 using a single dose of Ivermectin (IvermecPrev-Brazil) in the general asymptomatic susceptible population under SARS-CoV-2 exposition during a pandemic period in Brazil: randomized double-blind placebo-controlled trial

Federal University of Pernambuco0 个研究点目标入组 800 人开始时间: 2020年11月17日最近更新:
适应症

试验速览

阶段
3 期
状态
进行中(未招募)
发起方
入组人数
800

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Adult participants susceptible to be infected by SARS-CoV-19 (not previous infection) tested negative for IgM and IgG immunological test
  • 2. No symptoms of COVID-19
  • 3. Written informed consent signed by participating for the study

排除标准

  • 1. Pregnant or breastfeeding
  • 2. Known allergy to study medications used at intervention
  • 3. Known or reported history of liver disease
  • 4. Use of coumarin (anticoagulant)

研究者

发起方
Federal University of Pernambuco

相似试验